专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US6057102A HIV coreceptor mutants 失效
标题翻译： HIV共同受体突变体
公开(公告)号：US6057102A
公开(公告)日：2000-05-02
申请号：US907468
申请日：1997-08-08
申请人： Nathaniel R. Landau , Richard A. Koup , Rong Liu , William Paxton
发明人： Nathaniel R. Landau , Richard A. Koup , Rong Liu , William Paxton
IPC分类号： C07K14/715 , C12Q1/70 , C12Q1/68
CPC分类号： C12Q1/703 , C07K14/7158 , A01K2217/05 , C12Q2600/156
摘要： Entry of HIV-1 into target cells requires cell surface CD4 as well as additional host cell cofactors. A cofactor required for infection with virus adapted for growth in transformed T cell lines was recently identified and named fusin. Fusin, however, does not promote entry of macrophage-tropic viruses that are believed to be the key pathogenic strains in vivo. It has now been determined that the principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR5, a receptor for the .beta.-chemokines RANTES, MIP-1.alpha., and MIP-1.beta.. It has also been found that individuals who are homozygous for a mutation of the CKR-5 receptor are resistent to HIV infection; in vitro infection requires a 1000-fold higher dose of HIV than normal cells. The mutation results in complete suppression of CKR-5 expression.
摘要翻译： HIV-1进入靶细胞需要细胞表面CD4以及额外的宿主细胞辅因子。最近鉴定了一种在转化的T细胞系中适应生长的病毒感染所需的辅因子，并命名为fusin。然而，Fusin不促进被认为是体内关键致病菌株的巨噬细胞 - 嗜性病毒的进入。现在已经确定，由HIV-1的初级巨噬细胞 - 热带菌株的包膜糖蛋白引入的主要辅助因子是CC-CKR5，β-chemokines RANTES，MIP-1α和MIP-1β的受体。还发现对CKR-5受体的突变是纯合的个体对HIV感染是抗性的; 体外感染需要比正常细胞高1000倍的HIV。突变导致CKR-5表达的完全抑制。

2. 发明授权

US638796A Pencil-holder. 失效
公开(公告)号：US638796A
公开(公告)日：1899-12-12
申请号：US1899716514
申请日：1899-05-12
申请人： BURRIS WILLIAM PAXTON
发明人： BURRIS WILLIAM PAXTON
CPC分类号： B43K23/001

3. 发明授权

US09884788B2 Method for producing low porosity nonoxide ceramics 有权
公开(公告)号：US09884788B2
公开(公告)日：2018-02-06
申请号：US14611942
申请日：2015-02-02
申请人： Thomas Tsakalakos , Enver K. Akdogan , Ilyas Savkliyildiz , Hulya Bicer , Lawrence Kabacoff , Bart Visser , William Paxton
发明人： Thomas Tsakalakos , Enver K. Akdogan , Ilyas Savkliyildiz , Hulya Bicer , Lawrence Kabacoff , Bart Visser , William Paxton
IPC分类号： C04B35/64 , C04B35/515 , C04B35/563 , C04B35/56 , C04B35/565 , C04B35/58 , C04B35/583 , C04B35/584
CPC分类号： C04B35/563 , C04B35/5611 , C04B35/565 , C04B35/58057 , C04B35/58071 , C04B35/58078 , C04B35/583 , C04B35/584 , C04B2235/5445 , C04B2235/6562 , C04B2235/6567 , C04B2235/666 , C04B2235/77
摘要： The present invention relates to a method of producing ultra-high melting point nonoxide ceramics with low porosity based on sintering at low temperatures of below about 1000° C. with low DC electric fields of less than about 100 V/cm.

4. 发明授权

US1445796A Gauge for punching machines 失效
标题翻译：冲压机量规
公开(公告)号：US1445796A
公开(公告)日：1923-02-20
申请号：US50071321
申请日：1921-09-14
申请人： WILLIAM PAXTON LLOYD
发明人： WILLIAM PAXTON LLOYD
IPC分类号： B21D28/26
CPC分类号： B21D28/265 , Y10T83/654 , Y10T83/6566 , Y10T83/6569

5. 发明申请

US20090062377A1 ANTI-CANCER COMBINATIONS 审中-公开
标题翻译：抗癌联合
公开(公告)号：US20090062377A1
公开(公告)日：2009-03-05
申请号：US12264197
申请日：2008-11-03
申请人： Liang-Chuan Steve Wang , James William Paxton , Lai-Ming Ching , Bruce Charles Baguley , Philip Kestell
发明人： Liang-Chuan Steve Wang , James William Paxton , Lai-Ming Ching , Bruce Charles Baguley , Philip Kestell
IPC分类号： A61K31/352 , A61P35/04
CPC分类号： A61K45/06 , A61K31/352 , A61K2300/00
摘要： The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing said combinations.
摘要翻译：本发明涉及式I化合物的协同组合，例如呫吨酮乙酸类化合物如5,6-二甲基呫吨酮-4-乙酸（DMXAA）和NSAIDs，特别是双氯芬酸，其具有抗肿瘤活性。更具体地，本发明涉及这样的组合在治疗癌症中的用途以及含有所述组合的药物组合物。

6. 发明申请

US20160016857A1 METHOD FOR PRODUCING LOW POROSITY NONOXIDE CERAMICS 有权
标题翻译：生产低孔径非氧化物陶瓷的方法
公开(公告)号：US20160016857A1
公开(公告)日：2016-01-21
申请号：US14611942
申请日：2015-02-02
申请人： Thomas Tsakalakos , Enver K. Akdogan , Ilyas Savkliyildiz , Hulya Bicer , Lawrence Kabacoff , Bart Visser , William Paxton
发明人： Thomas Tsakalakos , Enver K. Akdogan , Ilyas Savkliyildiz , Hulya Bicer , Lawrence Kabacoff , Bart Visser , William Paxton
IPC分类号： C04B35/64 , C04B35/563
CPC分类号： C04B35/563 , C04B35/5611 , C04B35/565 , C04B35/58057 , C04B35/58071 , C04B35/58078 , C04B35/583 , C04B35/584 , C04B2235/5445 , C04B2235/6562 , C04B2235/6567 , C04B2235/666 , C04B2235/77
摘要： The present invention relates to a method of producing ultra-high melting point nonoxide ceramics with low porosity based on sintering at low temperatures of below about 1000° C. with low DC electric fields of less than about 100 V/cm.
摘要翻译：本发明涉及在小于约100V / cm的低DC电场下，在低于约1000℃的低温烧结下生产具有低孔隙率的超高熔点非氧化物陶瓷的方法。

7. 发明授权

US07462642B2 Anti-cancer combinations 失效
标题翻译：抗癌组合
公开(公告)号：US07462642B2
公开(公告)日：2008-12-09
申请号：US10946833
申请日：2004-09-22
申请人： Liang-Chuan Steve Wang , James William Paxton , Lai-Ming Ching , Bruce Charles Baguley , Philip Kestell
发明人： Liang-Chuan Steve Wang , James William Paxton , Lai-Ming Ching , Bruce Charles Baguley , Philip Kestell
IPC分类号： A61K31/35
CPC分类号： A61K45/06 , A61K31/352 , A61K2300/00
摘要： The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumor activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing said combinations.
摘要翻译：本发明涉及式I化合物的协同组合，例如呫吨酮乙酸类化合物如5,6-二甲基呫吨酮-4-乙酸（DMXAA）和NSAIDs，特别是双氯芬酸，其具有抗肿瘤活性。更具体地，本发明涉及这样的组合在治疗癌症中的用途以及含有所述组合的药物组合物。

8. 发明授权

US1087028A Headlight. 失效
公开(公告)号：US1087028A
公开(公告)日：1914-02-10
申请号：US1913785029
申请日：1913-08-16
申请人： WILLIAM PAXTON , MAPHIS CHARLES OWEN
发明人： MAPHIS CHARLES OWEN
CPC分类号： B60Q1/068

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式